941 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Monday’s Close
GILD Gilead Sciences, Inc. $72.78 $94.35B N/A
Article Searches
3 Big Biotechs Hold Growth Potential in Second Half of 2019 http://www.zacks.com/stock/news/432820/3-big-biotechs-hold-growth-potential-in-second-half-of-2019?cid=CS-ZC-FT-432820 Jun 21, 2019 - We highlight a few leading players from the biotech sector, having surpassed the same so far in 2019 and are likely to put up a good show during the second half of 2019 as well.
Gilead (GILD) Teams Up With Nurix for Cancer and Other Drugs http://www.zacks.com/stock/news/432004/gilead-gild-teams-up-with-nurix-for-cancer-and-other-drugs?cid=CS-ZC-FT-432004 Jun 20, 2019 - Gilead (GILD) collaborates with Nurix Therapeutics to leverage the proprietary drug discovery platform of the latter to identify novel agents that induce degradation of specified drug targets.
Big Drugmakers That May Tread the M&A Path After Pfizer http://www.zacks.com/stock/news/431504/big-drugmakers-that-may-tread-the-ma-path-after-pfizer?cid=CS-ZC-FT-431504 Jun 19, 2019 - There has been a flurry of M&A deal announcements this year in the drug industry. Here we discuss three big drug/biotech companies, which may make the next M&A move.
3 Big Drugmakers Most Likely to Make Acquisitions After Pfizer's Surprise Deal https://www.fool.com/investing/2019/06/18/3-big-drugmakers-most-likely-to-make-acquisitions.aspx?source=iedfolrf0000001 Jun 18, 2019 - Pfizer could be only the first of several to spend billions buying smaller biotech.
AstraZeneca Gives Detailed Data From Calquence Leukemia Study http://www.zacks.com/stock/news/430525/astrazeneca-gives-detailed-data-from-calquence-leukemia-study?cid=CS-ZC-FT-430525 Jun 17, 2019 - AstraZeneca's (AZN) Calquence monotherapy prolongs progression-free survival significantly in relapsed or refractory CLL patients compared to Roche's Rituxan.
GILD vs. ILMN: Which Stock Is the Better Value Option? http://www.zacks.com/stock/news/429670/gild-vs-ilmn-which-stock-is-the-better-value-option?cid=CS-ZC-FT-429670 Jun 14, 2019 - GILD vs. ILMN: Which Stock Is the Better Value Option?
CymaBay Down on Dismal Interim Data From Mid-Stage NASH Study http://www.zacks.com/stock/news/428755/cymabay-down-on-dismal-interim-data-from-mid-stage-nash-study?cid=CS-ZC-FT-428755 Jun 12, 2019 - CymaBay (CBAY) plummets as a phase IIb study on lead candidate, seladelpar, fails to show meaningful reductions in liver fat.
Gilead Sciences, Inc. (GILD) CEO Daniel O'Day presents at Jefferies 2019 Global Healthcare Brokers Conference (Transcript) https://seekingalpha.com/article/4268488-gilead-sciences-inc-gild-ceo-daniel-oday-presents-jefferies-2019-global-healthcare-brokers?source=feed_sector_healthcare Jun 05, 2019 - Gilead Sciences, Inc. (NASDAQ:GILD) Jefferies 2019 Global Healthcare Brokers Conference June 5, 2019 11:30 am ET Corporate Participants Daniel O’Day - Chairman and Chief Executive Officer Conference C
5 Biotech Stocks to Buy Right Now http://www.zacks.com/stock/news/424754/5-biotech-stocks-to-buy-right-now?cid=CS-ZC-FT-424754 Jun 04, 2019 - here are a few stocks that have outperformed their peers and are expected to have continued growth throughout the next couple of years. All the stocks in this list are a Zacks Rank #2 (Buy) or better.
Gilead Presents Data on CAR T Cell Therapy Candidate at ASCO http://www.zacks.com/stock/news/423909/gilead-presents-data-on-car-t-cell-therapy-candidate-at-asco?cid=CS-ZC-FT-423909 Jun 03, 2019 - Gilead (GILD) presents data from a phase I study on experimental CAR T cell therapy, KTE-X19, at ASCO and announces collaboration with Humanigen.

Pages: 123456...95

Page 1>